Tiny warriors, big impact: Targeted immunotherapy in kidney diseases - PubMed
3 hours ago
- #immunotherapy
- #kidney diseases
- #CAR-T cells
- Recent advances in immunotherapy targeting B cells have introduced new treatment possibilities for kidney diseases.
- CD19+ CAR-T cell therapy has shown efficacy and safety in treating therapy-resistant systemic lupus erythematosus (SLE), leading to clinical remission.
- Autoreactive B cells play a key role in SLE, lupus nephritis, and other inflammatory kidney diseases like ANCA-associated vasculitis and IgA-associated nephropathy.
- Current treatments often fail, resulting in high rates of disease progression or recurrence.
- Novel B cell-targeting immunotherapies may offer more effective and sustained suppression of autoimmunity compared to conventional anti-CD20 antibody therapy.
- Limited data exists on the application of these therapies in kidney diseases, necessitating further research on renal endpoints like proteinuria reduction and eGFR stabilization.
- This review summarizes kidney-specific applications and side effects of new immunotherapies, including CAR-T cells and T cell engagers, and discusses emerging approaches.